Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-31

Study Completion Date

2024-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is a randomized phase II clinical study, unicentre aimed to evaluate the tolerability, safety and efficacy of 18-Methoxyoronaridine as a candidate of tegumentary leishmaniasis treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)

NCT00600548

Treatment of Cutaneous Leishmaniasis in Brazil.

COMPLETED PHASE2

Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis

NCT06011343

Cutaneous Leishmaniasis, American

UNKNOWN PHASE2/PHASE3

Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.

NCT00471705

Cutaneous Leishmaniasis

COMPLETED PHASE3

Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.

NCT06000514

Cutaneous Leishmaniasis, American

COMPLETED PHASE1/PHASE2

Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia

NCT00487253

Cutaneous Leishmaniasis

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leishmaniasis; American, Cutaneous Drug Side Effect

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Drug under evaluation for leishmaniasis treatment

Intervention Type DRUG

Glucantime

Leishmaniasis standard drug in Brazil

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 and 59 years of age;
* Clinical diagnosis of leishmaniasis with at least one ulcerated lesion with evolution time from one month;
* Parasitological confirmation;
* Women of childbearing potential should not be pregnant or breastfeeding, confirmed by examination of b-HCG (Gonadotrophic-Chorionic Hormone beta) at the time of screening;
* Men and women should use barrier contraceptive methods during the course of the study;

Exclusion Criteria

* History of any disease or comorbidities that, in the opinion of the investigator, can either put the individual at risk or influence the results and ability of the subject to participate in the study;
* History or presence of gastrointestinal, hepatic, cardiac, renal disease or any other known condition that may interfere with the absorption, distribution, metabolism or excretion of the investigational product;
* Any evidence of underlying serious disease (cardiac, renal, hepatic or pulmonary);
* Pregnancy or the patient's unwillingness to use barrier contraceptive methods during and 3 months after therapy;
* History of gastrointestinal ulcer disease, inflammatory bowel disease, symptoms of indigestion;
* Any clinically important abnormality in biochemistry, hematology, urinalysis or clinical outcomes judged by the investigator;
* Any positive screening result for hepatitis B antigens, hepatitis C antibodies, and human immunodeficiency virus (HIV);
* Any clinically significant abnormalities in the rate, or driving the resting ECG morphology that may interfere with the interpretation of the QT interval variations;
* History of cancer;
* History of drug abuse, judging by the investigator
* History of alcohol abuse or excessive alcohol consumption, judged by the investigator;
* History of smoking
* History of severe allergy / hypersensitivity, judged by the investigator;
* History of hypersensitivity to drugs with similar chemical structure.

Minimum Eligible Age

18 Years

Maximum Eligible Age

59 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No